OncoMatch/Clinical Trials/NCT06520163
Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma
Is NCT06520163 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments for non-hodgkin's lymphoma.
Treatment: Etoposide · Cytarabine · PEG-rhG-CSF · G-CSF · CHOP · Hyper-CVAD · ID-MTX + Ara-C · DA-EPOCH · GDP · GDPE · ICE · DICE · G-CSF — This study utilizes a prospective, multicenter, randomized two-arm design to evaluate the efficacy and safety of the etoposide, cytarabine, and pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) combination therapy (EAP regimen) in mobilizing hematopoietic stem cells in patients with non-Hodgkin's lymphoma (NHL). A total of 99 NHL patients will be enrolled as research subjects and will be randomly allocated in a 2:1 ratio to compare the EAP regimen versus disease-specific chemotherapy mobilization regimen. The primary endpoint is the proportion of patients achieving the ideal collection value after a single collection (CD34+ cells ≥5×10\^6/kg).
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: chemotherapy
Achieved complete remission after multiple courses of chemotherapy.
Cannot have received: hematopoietic stem cell mobilization
History of prior hematopoietic stem cell mobilization.
Lab requirements
Kidney function
Serum creatinine clearance rate ≤ 50% [excluded]
Liver function
Serum direct bilirubin (DBIL) more than twice of the upper limit of normal (ULN); ALT and AST more than three times the upper limit of normal (ULN) [excluded]
Cardiac function
Cardiac function class II or higher or cardiac ejection fraction < 40% [excluded]
Cardiac function class II or higher or cardiac ejection fraction < 40%. Serum direct bilirubin (DBIL) more than twice of the upper limit of normal (ULN). Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) more than three times the upper limit of normal (ULN). Serum creatinine clearance rate ≤ 50%.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify